Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Cerilliant
Medtronic
McKesson
Citi
Queensland Health
Fuji
Federal Trade Commission

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,670,384

« Back to Dashboard

Which drugs does patent 6,670,384 protect, and when does it expire?

Patent 6,670,384 protects IXEMPRA KIT and is included in one NDA.

Protection for IXEMPRA KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and one patent family members in thirty-five countries.
Summary for Patent: 6,670,384
Title: Methods of administering epothilone analogs for the treatment of cancer
Abstract:A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.
Inventor(s): Bandyopadhyay; Rebanta (Portage, MI), Malloy; Timothy M. (Yardley, PA), Panaggio; Andrea (West Windsor, NJ), Raghavan; Krishnaswamy Srinivas (Cranbury, NJ), Varia; Sailesh Amilal (Princeton Junction, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:10/055,653
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Process; Use; Formulation; Composition;

Drugs Protected by US Patent 6,670,384

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;IV (INFUSION) 022065-001 Oct 16, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;IV (INFUSION) 022065-002 Oct 16, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,670,384

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE40387 Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones ➤ Sign Up
6,576,651 Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones ➤ Sign Up
8,632,788 Parenteral formulation for epothilone analogs ➤ Sign Up
7,022,330 Parenteral formulation for epothilone analogs ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Colorcon
Federal Trade Commission
Dow
Julphar
Queensland Health
Boehringer Ingelheim
Cerilliant
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.